KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Recursion Pharmaceuticals (RXRX) Leases (2022 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Leases for 4 consecutive years, with $20.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Leases fell 69.32% year-over-year to $20.2 million, compared with a TTM value of $20.2 million through Dec 2025, down 69.32%, and an annual FY2025 reading of $20.2 million, down 69.32% over the prior year.
  • Leases was $20.2 million for Q4 2025 at Recursion Pharmaceuticals, down from $47.8 million in the prior quarter.
  • Across five years, Leases topped out at $65.9 million in Q4 2024 and bottomed at $20.2 million in Q4 2025.
  • Average Leases over 4 years is $38.9 million, with a median of $34.8 million recorded in 2022.
  • The sharpest move saw Leases soared 95.7% in 2024, then tumbled 69.32% in 2025.
  • Year by year, Leases stood at $33.3 million in 2022, then increased by 1.23% to $33.7 million in 2023, then skyrocketed by 95.7% to $65.9 million in 2024, then crashed by 69.32% to $20.2 million in 2025.
  • Business Quant data shows Leases for RXRX at $20.2 million in Q4 2025, $47.8 million in Q3 2025, and $50.3 million in Q2 2025.